The industry, patients, and clinicians should now seek a better understanding of the criteria and conditions, including any potential relationship with the health technology assessment review recommendations and any obligation on the company if DFMO does not successfully navigate the reimbursement process. …
Worth knowing the criteria used to justify the creation of the DFMO 'bridging' fund
July 16, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
A shorter name and bolder blue for Novo in global rebrand
September 15, 2026 - - Latest News -
Australia's 2026 flu vaccination season barely moves the needle on uptake
September 15, 2026 - - Latest News -
Persistent fatigue could be an overlooked sign of liver disease
September 15, 2026 - - Latest News -
Noxopharm moves lupus skin therapy toward next human trial
September 14, 2026 - - Australian Biotech -
Entropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends
September 14, 2026 - - Latest News -
Diabetes and cancer blood tests reach WA and NT patients under new Healius deal
September 14, 2026 - - Australian Biotech -
FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug
September 14, 2026 - - Australian Biotech